Paper11238696
Targeting ceramide metabolism--a strategy for overcoming drug resistance.
Senchenkov A and 2 others. J Natl Cancer Inst, 2001. Cited by 240 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targeting ceramide metabolism--a strategy for overcoming drug resistance. Papers, record 11238696. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11238696
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Ceramides | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Neoplasms | Major topic |
| Sphingosine | Major topic |
| Animals | |
| Apoptosis | |
| Drug Resistance, Multiple | |
| Glucosylceramides | |
| Humans | |
| Signal Transduction | |
| Sphingomyelins |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CA77632 | NCI NIH HHS | United States | R01CA077632 | PubMed and NIH |
Source NIH RePORTER
Cited by108
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 240 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42151151 | DKC1 promotes colorectal cancer progression and therapy resistance by dysregulating sphingolipid biosynthesis. | Nat Commun | 2026 | https://conductscience.org/library/papers/42151151 | PubMed |
| 41346814 | Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm. | Discoveries (Craiova) | 2025 | https://conductscience.org/library/papers/41346814 | PubMed |
| 41305332 | Pathogens That Rewrite the Rules: Ascoviruses, Elegant Manipulators of Cell Death Pathways and Architects of the Extracellular Viral Paradigm. | Pathogens | 2025 | https://conductscience.org/library/papers/41305332 | PubMed |
| 40880617 | The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics. | J Oncol Res Ther | 2024 | https://conductscience.org/library/papers/40880617 | PubMed |
| 40088396 | Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings. | Cancer Metastasis Rev | 2025 | https://conductscience.org/library/papers/40088396 | PubMed |
| 39397024 | A sphingolipid rheostat controls apoptosis versus apical cell extrusion as alternative tumour-suppressive mechanisms. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39397024 | PubMed |
| 39337463 | Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337463 | PubMed |
| 39337312 | The Drug Transporter P-Glycoprotein and Its Impact on Ceramide Metabolism-An Unconventional Ally in Cancer Treatment. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337312 | PubMed |
| 39125841 | Sphingosine 1-Phosphate Stimulates ER to Golgi Ceramide Traffic to Promote Survival in T98G Glioma Cells. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39125841 | PubMed |
| 39072358 | Application of sphingolipid-based nanocarriers in drug delivery: an overview. | Ther Deliv | 2024 | https://conductscience.org/library/papers/39072358 | PubMed |
| 38203654 | Central Role of β-1,4-GalT-V in Cancer Signaling, Inflammation, and Other Disease-Centric Pathways. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203654 | PubMed |
| 38136410 | Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38136410 | PubMed |
| 38078003 | Sphingolipids in mitochondria-from function to disease. | Front Cell Dev Biol | 2023 | https://conductscience.org/library/papers/38078003 | PubMed |
| 37335416 | Solid tumor treatment via augmentation of bioactive C6 ceramide levels with thermally ablative focused ultrasound. | Drug Deliv Transl Res | 2023 | https://conductscience.org/library/papers/37335416 | PubMed |
| 36831326 | Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. | Cells | 2023 | https://conductscience.org/library/papers/36831326 | PubMed |
| 36567598 | Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer. | Technol Cancer Res Treat | 2022 | https://conductscience.org/library/papers/36567598 | PubMed |
| 36142562 | Ceramide Metabolism Regulated by Sphingomyelin Synthase 2 Is Associated with Acquisition of Chemoresistance via Exosomes in Human Leukemia Cells. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36142562 | PubMed |
| 35487785 | Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. | Blood Rev | 2022 | https://conductscience.org/library/papers/35487785 | PubMed |
| 35004331 | The Role of Sphingolipids Metabolism in Cancer Drug Resistance. | Front Oncol | 2021 | https://conductscience.org/library/papers/35004331 | PubMed |
| 34888943 | Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia. | FASEB J | 2022 | https://conductscience.org/library/papers/34888943 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11238696
GET https://conductscience.org/api/papers/v1/11238696/cited_by?page=2